Home / Clinical Decision Support & Reference / OphtAI

OphtAI

by OphtAI · Based in France → — Artificial intelligence for ophthalmology

Ophthalmology

Website Demo Contact API Docs

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Subscription-based

Documentation Provided

Overview

OphtAI is an artificial intelligence platform developed by the French group Evolucare Technologies, designed to assist healthcare professionals in the early detection and screening of major retinal pathologies. The platform analyzes standard field color retinograph images in real-time to identify risks associated with Diabetic Retinopathy, Glaucoma, and Age-related Macular Degeneration (AMD).

The system offers a streamlined workflow: capture retinal images, send them to OphtAI for analysis via web, desktop application, or API, and receive detailed PDF reports within seconds. This rapid analysis includes photo quality assessment, severity rating for Diabetic Retinopathy, localization of detected lesions, and a confidence score for the findings.

OphtAI is built on a collaborative foundation, stemming from a project with AP-HP hospitals and the Latim research laboratory, ensuring a strong clinical and research basis. It aims to enhance screening capabilities, particularly in contexts facing a rise in chronic eye conditions and a shortage of ophthalmologists, by providing an efficient and reliable AI-powered diagnostic aid.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

Retinal photo analysis
Detection of Diabetic Retinopathy, Glaucoma, AMD
Real-time analysis
Detailed PDF reports
Photo quality assessment
Severity rating (Diabetic Retinopathy)
Location of detected lesions
Confidence score
Customizable summary report
Compatible with standard field color retinographs

Use Cases

Automated screening for retinal diseases
Early detection of diabetic retinopathy
Glaucoma risk assessment
AMD detection
Large-scale population screening programs
Support for ophthalmologists and general practitioners

What Physicians Need to Know

Evidence Base

OphtAI's algorithms are trained using large datasets, including over 800,000 images from patients screened in Paris hospitals, France, and validated on over 300,000 retinal images from over 23,000 military veterans. The solution is a result of clinical and scientific research, developed in partnership with AP-HP and its Ophdiat network, and the LATIM research laboratory (UBO/INSERM). OphtAI also provides guidance on management based on recommendations from professional societies.

Clinical Validation Studies

OphtAI has undergone clinical validation, including the OphtAI-Eval study, a prospective, multicenter, post-marketing clinical follow-up study to validate its diagnostic performance for automated screening of diabetic retinopathy (DR), diabetic macular edema (DME), glaucoma, Age-related Maculopathy (ARM), and Age-related Macular Degeneration (AMD). A large validation study published in the ADA Diabetes Care journal showed OphtAI DR to be the only participant providing better results than an ophthalmologist for DR assessment, with statistically better sensitivity than human screeners. In this multicenter study, OphtAI DR analyzed over 300,000 retinal images from more than 23,000 military veterans. OphtAI is a CE-marked medical device and is certified by Health Canada and under the UKCA register.

Alert Fatigue Management

OphtAI contributes to managing alert fatigue by automating the initial review of images and sorting cases by urgency, which helps prioritize patients and reduces repetitive tasks for medical staff. This allows specialists to focus on higher-value activities and complex cases.

Differential Diagnosis Support

OphtAI provides differential diagnosis support by detecting and grading the severity of diabetic retinopathy, diabetic macular edema, glaucoma, ARM, and AMD. It offers explicable results through lesion mapping (heatmaps) and confidence indexes, allowing users to understand the AI's decision-making process.

Guideline Update Frequency

While a specific update frequency for guidelines within OphtAI is not explicitly stated, the company emphasizes continuous research and development to expand its artificial intelligence to other imaging modalities and add new disease detections. They are working on releasing a version with 12 new detectors and predictive models to anticipate pathology evolution. Clinical practice guidelines, in general, are typically reviewed and revised every 2-5 years or when new evidence warrants.

Clinical Workflow Integration

OphtAI is designed for seamless integration into clinical workflows. It can be accessed via a web browser (OphtAI WEB), a desktop application (OphtAI APP) for automatic analysis of photos in a PC directory, or through an API for integration into partners' software offerings. It integrates with vendor-neutral data management platforms like Topcon's Harmony Referral System, allowing access regardless of the fundus camera used. The service can launch automatically, streamlining the process and saving significant time for medical staff. It also facilitates administrative management and care coordination by automating file classification, generating standardized reports, and feeding directly into patient medical records.

Decision Audit Trail

OphtAI generates customizable PDF reports that can include details by disease, confidence levels, and lesion mapping. These reports are certified as Medical Devices and can be anonymized on demand. The system also offers accessible patient history through a centralized electronic patient record when integrated with platforms like Evolucare's OphCare. The software design complies with security, traceability, and data protection requirements, processing data in accordance with GDPR. Patient images and data are deleted after processing for security and anonymization purposes.

Physician Tip

OphtAI acts as an expert 'second reader,' capable of analyzing thousands of images without fatigue or cognitive bias, helping to identify subtle abnormalities that might be missed by the human eye. The system provides explicable results with lesion mapping and confidence scores, aiding in understanding the AI's decision. It helps prioritize patients based on urgency, allowing you to focus your expertise on complex or urgent cases and optimize your time. The automated initial review and sorting of images can significantly reduce repetitive tasks, improving overall efficiency in your practice. Remember that AI is a complementary tool that enhances your capabilities, not a replacement for clinical judgment.

OphtAI offers flexible integration options, including a web interface, a desktop application, and an API for seamless integration into existing software and systems. It is compatible with any standard field color retinograph for image capture. Notably, OphtAI partners with Topcon Healthcare Solutions to integrate into their Harmony Referral System, a vendor-neutral data management platform, allowing access to OphtAI's AI services regardless of the color fundus device being used. This facilitates streamlined clinical workflows and provides a single-screen review of all data. The solution is also developed by Evolucare Technologies, a leading healthcare software publisher, suggesting potential for integration with their other offerings like the OphCare platform for centralized electronic patient records.

At a glance

Pricing Subscription-based

Deployment Cloud Hosted, On Premise, Web Based, Mobile App, API

Visit site

Details

Category	Clinical Decision Support & Reference, Ophthalmology AI, Radiology & Imaging AI
Pricing	Subscription-based — OphtAI offers a simple, no-commitment monthly subscription, including unlimited use.
Free Trial	Unknown
Deployment	Cloud-hosted, On-premise, Web-based, Mobile App, API
Mobile App	1
API Available	Unknown
Data Export	Unknown
Languages	English, French, Spanish
Target Size	All specialties, from liberal practices to clinics and mobile operations.
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	Unknown AI-estimated OphtAI is a Class IIa Medical Device certified in the European Union (compliant with ISO 13485), by Health Canada, and in the United Kingdom under the UKCA register. Registration with the Swissdamed register (Switzerland) is currently underway. OphtAI has stated that FDA certification is in progress and they aim to target the American market once FDA approval has been obtained. They were planning to file for FDA approval for their diabetic retinopathy solution in mid-2021.
GDPR	Unknown AI-estimated
Integrations
EHR	Not specified
Specialties	Ophthalmology

Social Proof

Customers	unknown
Notable	AP-HP hospitals (collaborative project)

What the Web Says

OphtAI is an AI-powered solution designed to assist ophthalmologists in screening and diagnosing retinal conditions like diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD). It aims to improve early detection, optimize medical resources, and streamline clinical workflows by automating image analysis and prioritizing urgent cases. The system has been developed through collaborative research and is CE and Health Canada certified.

Overall: Positive

Strengths

High diagnostic performance comparable to human experts, and in some cases, outperforming them, particularly in diabetic retinopathy detection.
Automated initial review of images, sorting cases by urgency, and significant time savings for medical staff by reducing repetitive tasks.
Ability to detect early abnormalities sometimes invisible to the naked eye, leading to quicker patient referrals for appropriate care.
Can be deployed in various settings (healthcare facilities, private practices, teleophthalmology) and is compatible with basic infrastructure, including slow internet connections.
Complies with regulatory and safety requirements, being CE and Health Canada certified (Class IIa), with environments certified for Health Data Hosting (HDS) and GDPR compliance.
Integration with existing IT tools and vendor-neutral data management platforms like Topcon Harmony, allowing seamless workflow integration.

Limitations

No specific negative reviews or opinions from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra were found for OphtAI directly. However, general concerns about AI in ophthalmology or medical scribes include potential for inaccuracies and the need for human oversight.
General AI chatbots may struggle with imaging diagnosis, lacking understanding of nuances in OCT scans.
Some AI medical scribes have been noted to produce weirdly formatted notes, miss key details, or summarize inaccurately for complex cases.
General AI tools might lack flexibility in templates and customization options.
Some AI solutions are slow to add new features.
Concerns exist about the authenticity of reviews on platforms like Capterra and G2, with some users reporting incentivized or fake reviews.

Based on reviews from: OphtAI : AI for ophthalmologists, Ophtai: Artificial intelligence for ophthalmology, AI in teleophthalmology: towards optimised eye screening - Ophtai, Comparing Ophthalmologist and Artificial Intelligence Chatbot Responses to Patient Questions - PMC, Study Examines the Quality and Empathy of AI Retina Consults - Review of Ophthalmology, How Good Is AI? A New Study Shows It Can Outperform Seasoned Ophthalmology Specialists - Mount Sinai, OPHTAI CONFIRMS ITS UNRIVALED PERFORMANCE AND EFFICIENCY IN A REAL-WORLD VALIDATION STUDY PUBLISHED IN THE ADA DIABETES CARE JOU - Evolucare, PR Harmony and OphtAI - Topcon Healthcare, AI: A health-care game changer is here | Ophthalmology Management, AI for studying or discussing cases, what's your take and which one is the best? - Reddit, OphthoACR (Ophthalmology Automated Chart Review): An AI-Powered Tool for Complete Automation of Ophthalmology Chart Reviews and Cohort Data Analysis | TVST, Topcon Healthcare and OphtAI Announce their Partnership in EMEA, OphthoACR (Ophthalmology Automated Chart Review): An AI-Powered Tool for Complete Automation of Ophthalmology Chart Reviews and Cohort Data Analysis - PMC, OphtAI at SANTEXPO 2026: AI for visual screening, AI programm : r/Ophthalmology - Reddit, Capterra Reviews & Ratings 2026 - TrustRadius, AI tool can scan your retina and predict your risk of heart disease 'in 60 seconds or less' : r/tech - Reddit, I tried a lot of AI medical scribes so you don't have to - my honest review : r/medicine - Reddit, Ophthalmology-Cloud Software Pricing, Alternatives & More 2026 | Capterra, I tried all the AI medical scribes so you don't have to - my honest review - Reddit, An AI-Powered Tool for Complete Automation of Ophthalmology Chart Reviews and Cohort Data Analysis | TVST, An AI-Powered Tool for Complete Automation of Ophthalmology Chart Reviews and Cohort Data Analysis | TVST | ARVO Journals, OfoxAI Software Pricing, Alternatives & More 2026 | Capterra, Dr. Audrey Tai, DO - Ophthalmologist in Mission Viejo, CA | Healthgrades, Capterra Pros and Cons | User Likes & Dislikes - G2, Is capterra good? - Quora, OphthoACR: An AI Tool for Automating Ophthalmology Chart Review and Data Extraction, G2 Reviews | Read Customer Service Reviews of www.g2.com - Trustpilot, Optux AI Reviews 2026: Details, Pricing, & Features - G2, Opteo Reviews 2026: Details, Pricing, & Features - G2, READ BEFORE BUYING Why is no one being honest about the Even Realities G2s? My honest review after 2 days. : r/EvenRealities - Reddit, Hostie AI Products | Read 23 Reviews on G2

Last updated: 2026-06-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate OphtAI

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

OphtAI News

OphtAI at SANTEXPO 2026: AI for visual screening

OphtAI will be exhibiting at the SANTEXPO trade fair in Paris from May 19-21, 2026, showcasing their artificial intelligence solution for retinal condition screening.

2026-04

OphtAI News

OphtAI : AI for ophthalmologists

This article discusses how AI, particularly OphtAI, is transforming ophthalmology by improving early detection of chronic conditions like diabetic retinopathy, glaucoma, and AMD, and optimizing medical resources.

2026-03

OphtAI News

Evolucare OphtAI CE certified according to the MDR

OphtAI, a medical AI solution in ophthalmology, has received CE Medical Device Certification according to the MDR, highlighting its compliance with European regulatory requirements for safety and reliability.

2025-12

OphtAI News

OphtAI at the Heart of the Artificial Intelligence Revolution in Ophthalmology

Alexandre Le Guilcher, Research & Innovation Director of Evolucare Technologies, discusses OphtAI's role in addressing the challenge of diabetic retinopathy screening and the ethical considerations of AI in medicine.

2025-08

PMC

A scoping review of artificial intelligence as a medical device for ophthalmic image analysis in Europe, Australia and America - PMC

This review identifies OphtAI as a CE Class IIa medical device in France, utilizing fundus photographs to detect and grade diabetic retinopathy, DMO, glaucoma, and AMD.

2025-05

Taylor & Francis

Comparison of 21 artificial intelligence algorithms in automated diabetic retinopathy screening using handheld fundus camera

OphtAI was one of 21 AI algorithms evaluated in a study comparing their effectiveness in automated diabetic retinopathy screening using handheld fundus cameras, with results showing varied agreement and performance among the algorithms.

2024-05

Ophthalmology Breaking News

Topcon Healthcare and OphtAI Announce their Partnership in EMEA

Topcon Healthcare Solutions and OphtAI have partnered to integrate OphtAI's AI algorithm into Topcon's Harmony Referral System, providing eye care professionals with enhanced access to AI services for early detection of eye pathologies.

2023-03

Optomed Plc Press Release

Optomed signs an industrial partnership with a French AI company OphtAI

Optomed and OphtAI have signed a commercial collaboration agreement to sell OphtAI's artificial intelligence for screening common eye diseases alongside Optomed Aurora handheld cameras, focusing on European countries and Canada.

2022-03

Videos

Product demos, reviews, and walkthroughs for OphtAI.

Demain La Tech avec OphtAI

demaintv

Arab Health 2020 - Ru00e9gion Hauts de France - Ophtai - Alexandre Le Guilcher

Mickael Genet

What are Eye Floaters? ufffc

Stay Curious, My Friends

June 6, 2024

Vijay Chauhan

ud83cudfac Clap de fin sur cette u00e9dition 2025 de #SANTEXPO !

Evolucare Technologies

Optomed Q3u201922: Kasvua haasteista huolimatta

inderesTV

View all on YouTube

Frequently Asked Questions

How does OphtAI integrate into my existing clinical workflow and EMR system?

OphtAI is designed for easy integration into your existing IT tools for patient care, often launching automatically without user intervention. It can be accessed via a web browser, a desktop application that detects photos in a PC directory, or an API for integration into partner software. While specific EMR integrations would need to be confirmed with OphtAI, AI-enabled EMR integration can support various tasks like documentation, referrals, treatment plan tracking, and analytics, ultimately streamlining workflows and reducing manual entry.

What are the regulatory approvals and compliance standards for OphtAI?

OphtAI is a Class IIa Medical Device, certified in the European Union (compliant with ISO 13485 and MDR 2017/745) and by Health Canada, with UKCA registration. It also anticipates compliance with the European AI Act. The solution adheres to GDPR for data protection and security, processing data in certified Health Data Hosting (HDS) environments, and does not store patient-related data for security and anonymization purposes.

How accurate and reliable is OphtAI in detecting ophthalmic conditions compared to human experts?

OphtAI has demonstrated high sensitivity and specificity in detecting retinal conditions, including diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD), with performance comparable to or even outperforming expert human readers. Studies have shown its ability to standardize image interpretation, reduce inter-observer variability, and effectively prioritize at-risk patients. It provides consistent and detailed feedback, including predictive values and heat maps, to help users understand the results.

What are the main limitations of using OphtAI in a clinical setting?

While powerful, AI tools like OphtAI do not replace clinical judgment; they enhance it. Limitations can include the need for huge databases for training, significant computing power, and increased processing time for complex neural networks. Also, AI generally detects more overt pathologies with higher accuracy compared to subtle findings. OphtAI specifically processes standard fundus examination images and does not process corneal images or retinal images from fluorescein angiography or other markers.

What are the alternatives to OphtAI for AI-powered clinical decision support in ophthalmology?

Several other AI tools and platforms offer clinical decision support in ophthalmology. Examples include Eyenuk EyeArt and IDx-DR for diabetic retinopathy screening, Optovue iWellness for retinal diseases, and RetInSight solutions for AMD monitoring. Other general clinical decision support systems like UpToDate Expert AI, DynaMed, and OpenEvidence are also available, though they may not be ophthalmology-specific.

What is the pricing model for OphtAI, and how can it impact the cost-effectiveness of my practice?

While specific pricing details are not publicly available, OphtAI operates on a credit-based system where users can buy credits for analyses. Studies suggest that using AI for diabetic retinopathy screening, such as OphtAI DR, can reduce screening costs, with one study indicating a reduction of more than $15 USD per patient. This cost-effectiveness stems from its ability to automate initial image review, sort cases by urgency, and save medical staff significant time by reducing repetitive tasks.

What specific ophthalmic conditions can OphtAI detect and assist with in diagnosis?

OphtAI is capable of detecting and assisting with the diagnosis of major retinal diseases, including diabetic retinopathy (DR), diabetic macular edema (DME), glaucoma, and age-related macular degeneration (AMD), including age-related maculopathy (ARM). It can also provide a severity rating for DR and identify the location of detected lesions.